Core Insights - The core viewpoint of the article highlights the significant market dynamics and competitive landscape of flow cytometers in China, particularly focusing on the impact of export restrictions on international brands and the rise of domestic manufacturers [1][2][4]. Market Overview - In the first half of 2025, the total bid amount for flow cytometers in China reached 230 million yuan, with 208 units awarded [4]. - Imported brands dominated the market, accounting for 91.89% of the bid amount and 85.29% of the bid quantity [4][6]. - The market is experiencing a structural transformation with an accelerated wave of localization, as international brands like Agilent and Beckman are launching localized models while domestic manufacturers are making breakthroughs in the mid-to-low-end market [2]. Competitive Landscape - BD was significantly impacted by U.S. export restrictions, allowing competitors like Beckman and Agilent to capture the top positions in both bid amount and quantity during the affected period [8]. - Beckman led the bid amount with a 27.41% share, followed by BD at 22.49% and Cytek at 15.95% [8]. - In terms of bid quantity, Agilent topped the list with a 36.65% share, largely due to a significant order from the Xinjiang CDC [10]. Domestic Manufacturers - Domestic brands such as Pukang Medical, Mindray, and Fuliu Bio have successfully entered the top ten in bid amounts, while brands like Prism Tech and Weigong are among the top ten in bid quantities [12]. - Other domestic players also gaining traction include Chenglang Bio, Urite, and Zhongsheng Medical [12]. Procurement Insights - The primary purchasers of flow cytometers are medical and research institutions, with hospitals accounting for the highest procurement amount at 44.63% [13]. - In terms of quantity, hospitals also lead with a 35.75% share, followed by disease control centers and universities [15]. Pricing Trends - The majority of flow cytometers awarded in bids were priced below 800,000 yuan, with those under 200,000 yuan making up the largest share at 28.23% [17]. - A record bid price of 9.795 million yuan was set for a mass spectrometry flow cytometer from Standard BioTools, surpassing the previous record held by BD [19].